Trials / Completed
CompletedNCT04242446
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 505 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-specified time-points. |
| OTHER | Placebo | Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period. |
Timeline
- Start date
- 2020-02-19
- Primary completion
- 2022-04-07
- Completion
- 2023-02-19
- First posted
- 2020-01-27
- Last updated
- 2026-04-14
- Results posted
- 2025-01-09
Locations
88 sites across 15 countries: United States, Australia, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Spain, Switzerland, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04242446. Inclusion in this directory is not an endorsement.